Protective prototype-Beta and Delta-Omicron chimeric RBD-dimer vaccines against SARS-CoV-2Vaccine immunogens designed as chimeras of the spike protein receptor binding domain of two distinct SARS-CoV-2 variants elicit broad serum neutralization and protection from infection by the beta, delta, and omicron variants in mouse and macaque. The chimeric approach is applicable for rapid updating of immunogens against both circulating and emerging variants.Vaccine immunogens designed as chimeras of the spike protein receptor binding domain of two distinct SARS-CoV-2 variants elicit broad serum neutralization and protection from infection by the beta, delta, and omicron variants in mouse and macaque. The chimeric approach is applicable for rapid updating of immunogens against both circulating and emerging variants.Kun Xu, Ping Gao, Sheng Liu, Shuaiyao Lu, Wenwen Lei, Tianyi Zheng, Xueyuan Liu, Yufeng Xie, Zhennan Zhao, Shuxin Guo, Cong Tang, Yun Yang, Wenhai Yu, Junbin Wang, Yanan Zhou, Qing Huang, Chuanyu Liu, Yaling An, Rong Zhang, Yuxuan Han, Minrun Duan, Shaofeng Wang, Chenxi Yang, Changwei Wu, Xiaoya Liu, Guangbiao She, Yan Liu, Xin Zhao, Ke Xu, Jianxun Qi, Guizhen Wu, Xiaozhong Peng, Lianpan Dai, Peiyi Wang, George F. Gaohttps://secure.jbs.elsevierhealth.com/action/getSharedSiteSession?redirect=https%3A%2F%2Fwww.cell.com%2Fcell%2Ffulltext%2FS0092-8674%2822%2900527-X%3Frss%3Dyes&rc=0http://www.cell.com/cell/inpress.rssCellCell RSS feed.Wireless News CampaignApril 27, 2022

Powered by WPeMatico